Pyxis Oncology Inc
NASDAQ:PYXS
Intrinsic Value
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PYXS.
Pyxis Oncology Inc's market capitalization is 250m USD.
PYXS stock price is 4.3 USD.
PYXS.
PYXS. Open DCF Valuation
PYXS. Open Relative Valuation
PYXS has upside potential of 90% compared to the average analyst price target.
Open Wall St Estimates
PYXS has negative Free Cash Flow for the last twelve months.
PYXS has negative Operating Income for the last twelve months.
PYXS has negative Net Income for the last twelve months.
PYXS's ROE (Return on Equity) for the past 12 months is negative and is equal to -52%.
PYXS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -218%.
PYXS's long-term assets (174m USD) exceed its long-term liabilties (48m USD).
PYXS has negative three-year average ROE (Return on Equity): -49%. The company is not efficient at transforming stockholders' equity into net income.
PYXS has negative three-year average ROIC (Return on Invested Capital): -804%. The company is not efficient at using invested capital to generate operating income.
PYXS's short-term assets (125m USD) exceed its short-term liabilties (26m USD).
PYXS's D/E (Debt to Equity) is very low and is equal to 0.
PYXS's Altman Z-Score is very low and is equal to -2.7.
Fundamental Analysis
Pyxis Oncology Inc
Balance Sheet Decomposition
Pyxis Oncology Inc
| Current Assets | 124.6m |
| Cash & Short-Term Investments | 119.3m |
| Other Current Assets | 5.3m |
| Non-Current Assets | 49.1m |
| PP&E | 24.8m |
| Intangibles | 24.3m |
| Current Liabilities | 25.8m |
| Accounts Payable | 3.9m |
| Accrued Liabilities | 14.2m |
| Other Current Liabilities | 7.7m |
| Non-Current Liabilities | 22.3m |
| Other Non-Current Liabilities | 22.3m |
Earnings Waterfall
Pyxis Oncology Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-82.2m
USD
|
|
Operating Income
|
-82.2m
USD
|
|
Other Expenses
|
8.4m
USD
|
|
Net Income
|
-73.8m
USD
|
Free Cash Flow Analysis
Pyxis Oncology Inc
PYXS Profitability Score
Profitability Due Diligence
Pyxis Oncology Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Pyxis Oncology Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PYXS Solvency Score
Solvency Due Diligence
Pyxis Oncology Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Pyxis Oncology Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYXS Price Targets Summary
Pyxis Oncology Inc
According to Wall Street analysts, the average 1-year price target for
PYXS
is 8.16 USD
with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Ownership
PYXS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PYXS Price
Pyxis Oncology Inc
| Average Annual Return | -58.25% |
| Standard Deviation of Annual Returns | 41.98% |
| Max Drawdown | -93% |
| Market Capitalization | 250m USD |
| Shares Outstanding | 58 133 400 |
| Percentage of Shares Shorted | 5.58% |
Company Profile
Pyxis Oncology Inc
Country
Industry
Market Cap
Dividend Yield
Description
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm has developed a portfolio of antibody drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that are developing as monotherapies and in combination with other therapies. Its pipeline includes PYX-106, PYX-102, PYX-201, PYX-202 and PYX-203. Its PYX-106 is an investigational, fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15-mediated suppression of T-cell proliferation and function. PYX-102 is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. PYX-201 is an investigational ADC consisting of an immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B (EDB), mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker.
You don't have any saved screeners yet
